IL162979A - 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder - Google Patents

4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder

Info

Publication number
IL162979A
IL162979A IL162979A IL16297904A IL162979A IL 162979 A IL162979 A IL 162979A IL 162979 A IL162979 A IL 162979A IL 16297904 A IL16297904 A IL 16297904A IL 162979 A IL162979 A IL 162979A
Authority
IL
Israel
Prior art keywords
methyl
preparation
pharmaceutical compositions
phenyl
oxido
Prior art date
Application number
IL162979A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9929594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL162979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL162979A publication Critical patent/IL162979A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
IL162979A 2002-01-23 2004-07-12 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder IL162979A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds
PCT/EP2003/000613 WO2003062220A1 (en) 2002-01-23 2003-01-22 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
IL162979A true IL162979A (en) 2010-12-30

Family

ID=9929594

Family Applications (2)

Application Number Title Priority Date Filing Date
IL162979A IL162979A (en) 2002-01-23 2004-07-12 4-[(4-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide, pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder
IL208399A IL208399A (en) 2002-01-23 2010-10-03 4-[(4-methyl-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide,pharmaceutical compositions comprising it and use thereof for the preparation of a pharmaceutical composition for the treatment of a proliferative disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL208399A IL208399A (en) 2002-01-23 2010-10-03 4-[(4-methyl-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide,pharmaceutical compositions comprising it and use thereof for the preparation of a pharmaceutical composition for the treatment of a proliferative disorder

Country Status (15)

Country Link
US (5) US7557105B2 (enExample)
EP (3) EP2194049B1 (enExample)
JP (2) JP4213595B2 (enExample)
KR (2) KR20070058019A (enExample)
CN (2) CN100467461C (enExample)
AT (1) ATE380807T1 (enExample)
BR (1) BR0307058A (enExample)
CA (1) CA2474104C (enExample)
DE (1) DE60318013T2 (enExample)
ES (2) ES2294293T3 (enExample)
GB (1) GB0201508D0 (enExample)
IL (2) IL162979A (enExample)
MX (1) MXPA04007130A (enExample)
PT (2) PT2194049E (enExample)
WO (1) WO2003062220A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
US8969379B2 (en) * 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) * 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
KR101353763B1 (ko) * 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
ME00011A (me) * 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
CN104706637A (zh) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090324718A1 (en) * 2006-09-01 2009-12-31 Ilan Zalit Imatinib compositions
WO2008051597A1 (en) * 2006-10-26 2008-05-02 Sicor Inc. Process for the preparation of imatinib
EP1988089A1 (en) * 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物，制备方法及其用途
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2166858A4 (en) 2007-06-07 2011-08-03 Intra Cellular Therapies Inc NEW HETEROCYCLIC COMPOUNDS AND ITS USE
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
CA2704000C (en) * 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009096377A1 (ja) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. 血管阻害物質とタキサンとの併用
EP2255192A1 (en) * 2008-03-26 2010-12-01 Merck Patent GmbH Method of long term storage of substrate-coupled beads
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Also Published As

Publication number Publication date
KR20040081467A (ko) 2004-09-21
JP5027076B2 (ja) 2012-09-19
IL208399A0 (en) 2010-12-30
GB0201508D0 (en) 2002-03-13
EP2194049B1 (en) 2014-08-13
CN100467461C (zh) 2009-03-11
EP1470120A1 (en) 2004-10-27
JP4213595B2 (ja) 2009-01-21
JP2005519908A (ja) 2005-07-07
CA2474104C (en) 2012-04-17
US20090239879A1 (en) 2009-09-24
DE60318013D1 (de) 2008-01-24
US20140323494A1 (en) 2014-10-30
DE60318013T2 (de) 2008-11-13
KR100778163B1 (ko) 2007-11-28
WO2003062220A1 (en) 2003-07-31
JP2009051837A (ja) 2009-03-12
ATE380807T1 (de) 2007-12-15
EP1783126A3 (en) 2008-11-26
EP1783126A2 (en) 2007-05-09
IL208399A (en) 2013-02-28
US20050209452A1 (en) 2005-09-22
ES2503734T3 (es) 2014-10-07
MXPA04007130A (es) 2004-10-29
EP2194049A1 (en) 2010-06-09
US20100222362A1 (en) 2010-09-02
ES2294293T3 (es) 2008-04-01
CN101468984A (zh) 2009-07-01
BR0307058A (pt) 2004-12-28
PT1470120E (pt) 2008-03-03
EP1470120B1 (en) 2007-12-12
US7557105B2 (en) 2009-07-07
KR20070058019A (ko) 2007-06-07
CN1646519A (zh) 2005-07-27
CA2474104A1 (en) 2003-07-31
US20110294820A1 (en) 2011-12-01
PT2194049E (pt) 2014-11-10

Similar Documents

Publication Publication Date Title
IL208399A0 (en) 4-[(-methyl-4-oxido-1-piperazinyl)-methyl]-n-{4-methyl-3[[4-(3-pyridinyl)-2-pyrimidinyl]-amino]-phenyl}-benzamide,pharmaceutical compositions comprising it and use thereof for the preparation of medicaments for the treatment of a proliferative disorder
IL163090A (en) Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JO2371B1 (en) 4-phenyl-pyridine derivatives
DE602004026068D1 (de) Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
SI1425277T1 (sl) Seäśninske spojine, aktivne kot vaniloidni receptorski antagonisti za zdravljenje boleäśine
CY1109925T1 (el) Η χρηση πυριδυλ αμιδιων ως παρεμποδιστων της αγγειογενεσης
IL184353A0 (en) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted-phenyl)methanone derivatives as glycine transporter 1 (glyt-1)inhibitors for the treatment of neurological and neuropsychiatric disorders
IL161092A0 (en) N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds
IS6925A (is) Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
CA2730471A1 (en) Piperazine derivatives used as cav2.2 calcium channel modulators
TW200716618A (en) Chemical compounds
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
ATE450498T1 (de) Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
DE60322110D1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
TW200634002A (en) Chemical compounds
SE0102809D0 (sv) Novel compounds
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
MXPA06001226A (es) Derivados de 2-4??-(2 -hidroximetil -fenilamino)-piperidin -1-il-n-(9h- carbazol-3- il)-acetamina y compuestos relacionados como ligandos del neuropeptido y5 (npy5) para el tratamiento de la obesidad.
ZA200706705B (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof